APO Research
Talk to an analyst

APO RESEARCH · REPORT

Enasidenib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Enasidenib Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchEnasidenib Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Enasidenib Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Enasidenib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Enasidenib Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Enasidenib Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Enasidenib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Enasidenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Enasidenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Enasidenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Enasidenib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Enasidenib market include Bristol Myers Squibb. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Enasidenib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Enasidenib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Enasidenib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Enasidenib market size, projected growth trends, production technologies, key applications, and end-use industries.

Enasidenib Segment by Company

Bristol Myers Squibb

Enasidenib Segment by Type

100mg

50mg

Enasidenib Segment by Application

Hospital

Pharmacy

Enasidenib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Enasidenib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Enasidenib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Enasidenib significant trends, drivers, influence factors in global and regions.

6. To analyze Enasidenib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Enasidenib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Enasidenib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Enasidenib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Enasidenib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Enasidenib industry.

Chapter 3: Detailed analysis of Enasidenib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Enasidenib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Enasidenib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Enasidenib Industry Trends Table 2. Enasidenib Industry Drivers Table 3. Enasidenib Industry Opportunities and Challenges Table 4. Enasidenib Industry Restraints Table 5. Global Enasidenib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Enasidenib Revenue Share by Company (2021-2026) Table 7. Global Enasidenib Sales Volume by Company (units) & (2021-2026) Table 8. Global Enasidenib Sales Volume Share by Company (2021-2026) Table 9. Global Enasidenib Average Price (US$/unit) of Company (2021-2026) Table 10. Global Enasidenib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Enasidenib Key Company Manufacturing Base & Headquarters Table 12. Global Enasidenib Company, Product Type & Application Table 13. Global Enasidenib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Enasidenib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg Table 18. Significant Companies of 50mg Table 19. Global Enasidenib Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 20. Global Enasidenib Sales Volume by Type (2021-2026) & (units) Table 21. Global Enasidenib Sales Volume by Type (2027-2032) & (units) Table 22. Global Enasidenib Sales Volume Share by Type (2021-2026) Table 23. Global Enasidenib Sales Volume Share by Type (2027-2032) Table 24. Global Enasidenib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Enasidenib Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Enasidenib Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Enasidenib Sales Value Share by Type (2021-2026) Table 28. Global Enasidenib Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Global Enasidenib Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 32. Global Enasidenib Sales Volume by Application (2021-2026) & (units) Table 33. Global Enasidenib Sales Volume by Application (2027-2032) & (units) Table 34. Global Enasidenib Sales Volume Share by Application (2021-2026) Table 35. Global Enasidenib Sales Volume Share by Application (2027-2032) Table 36. Global Enasidenib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Enasidenib Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Enasidenib Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Enasidenib Sales Value Share by Application (2021-2026) Table 40. Global Enasidenib Sales Value Share by Application (2027-2032) Table 41. Global Enasidenib Sales by Region: 2021 VS 2025 VS 2032 (units) Table 42. Global Enasidenib Sales by Region (2021-2026) & (units) Table 43. Global Enasidenib Sales Market Share by Region (2021-2026) Table 44. Global Enasidenib Sales by Region (2027-2032) & (units) Table 45. Global Enasidenib Sales Market Share by Region (2027-2032) Table 46. Global Enasidenib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Enasidenib Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Enasidenib Sales Value Share by Region (2021-2026) Table 49. Global Enasidenib Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Enasidenib Sales Value Share by Region (2027-2032) Table 51. Global Enasidenib Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Enasidenib Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Enasidenib Sales by Country: 2021 VS 2025 VS 2032 (units) Table 54. Global Enasidenib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Enasidenib Sales by Country (2021-2026) & (units) Table 56. Global Enasidenib Sales Market Share by Country (2021-2026) Table 57. Global Enasidenib Sales by Country (2027-2032) & (units) Table 58. Global Enasidenib Sales Market Share by Country (2027-2032) Table 59. Global Enasidenib Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Enasidenib Sales Value Market Share by Country (2021-2026) Table 61. Global Enasidenib Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Enasidenib Sales Value Market Share by Country (2027-2032) Table 63. Bristol Myers Squibb Company Information Table 64. Bristol Myers Squibb Business Overview Table 65. Bristol Myers Squibb Enasidenib Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Bristol Myers Squibb Enasidenib Product Portfolio Table 67. Bristol Myers Squibb Recent Development Table 68. Key Raw Materials Table 69. Raw Materials Key Suppliers Table 70. Enasidenib Distributors List Table 71. Enasidenib Customers List Table 72. Research Programs/Design for This Report Table 73. Authors List of This Report Table 74. Secondary Sources Table 75. Primary Sources List of Figures Figure 1. Enasidenib Product Image Figure 2. Global Enasidenib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Enasidenib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Enasidenib Sales (2021-2032) & (units) Figure 5. Global Enasidenib Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Enasidenib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg Image Figure 10. 50mg Image Figure 11. Global Enasidenib Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 12. Global Enasidenib Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Enasidenib Sales Volume Share by Type (2021-2032) Figure 14. Global Enasidenib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Enasidenib Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Enasidenib Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Global Enasidenib Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 20. Global Enasidenib Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Enasidenib Sales Volume Share by Application (2021-2032) Figure 22. Global Enasidenib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Enasidenib Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Enasidenib Sales Value Share by Application (2021-2032) Figure 25. Global Enasidenib Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 26. Global Enasidenib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Enasidenib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Enasidenib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Enasidenib Sales Value (2021-2032) & (US$ Million) Figure 30. North America Enasidenib Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Enasidenib Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Enasidenib Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Enasidenib Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Enasidenib Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Enasidenib Sales Value (2021-2032) & (US$ Million) Figure 36. South America Enasidenib Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Enasidenib Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Enasidenib Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Enasidenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Enasidenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Enasidenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Enasidenib Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Enasidenib Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg
  • 50mg
Applications
  • Hospital
  • Pharmacy
Companies covered
  • Bristol Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Enasidenib Sales Value (2021-2032)
  4. 1.2.2 Global Enasidenib Sales Volume (2021-2032)
  5. 1.2.3 Global Enasidenib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Enasidenib Market Dynamics
  1. 2.1 Enasidenib Industry Trends
  2. 2.2 Enasidenib Industry Drivers
  3. 2.3 Enasidenib Industry Opportunities and Challenges
  4. 2.4 Enasidenib Industry Restraints
3 Enasidenib Market by Company
  1. 3.1 Global Enasidenib Company Revenue Ranking in 2025
  2. 3.2 Global Enasidenib Revenue by Company (2021-2026)
  3. 3.3 Global Enasidenib Sales Volume by Company (2021-2026)
  4. 3.4 Global Enasidenib Average Price by Company (2021-2026)
  5. 3.5 Global Enasidenib Company Ranking (2024-2026)
  6. 3.6 Global Enasidenib Company Manufacturing Base and Headquarters
  7. 3.7 Global Enasidenib Company Product Type and Application
  8. 3.8 Global Enasidenib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Enasidenib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Enasidenib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Enasidenib Market by Type
  1. 4.1 Enasidenib Type Introduction
  2. 4.1.1 100mg
  3. 4.1.2 50mg
  4. 4.2 Global Enasidenib Sales Volume by Type
  5. 4.2.1 Global Enasidenib Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Enasidenib Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Enasidenib Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Enasidenib Sales Value by Type
  9. 4.3.1 Global Enasidenib Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Enasidenib Sales Value by Type (2021-2032)
  11. 4.3.3 Global Enasidenib Sales Value Share by Type (2021-2032)
5 Enasidenib Market by Application
  1. 5.1 Enasidenib Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Enasidenib Sales Volume by Application
  5. 5.2.1 Global Enasidenib Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Enasidenib Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Enasidenib Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Enasidenib Sales Value by Application
  9. 5.3.1 Global Enasidenib Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Enasidenib Sales Value by Application (2021-2032)
  11. 5.3.3 Global Enasidenib Sales Value Share by Application (2021-2032)
6 Enasidenib Regional Sales and Value Analysis
  1. 6.1 Global Enasidenib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Enasidenib Sales by Region (2021-2032)
  3. 6.2.1 Global Enasidenib Sales by Region: 2021-2026
  4. 6.2.2 Global Enasidenib Sales by Region (2027-2032)
  5. 6.3 Global Enasidenib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Enasidenib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Enasidenib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Enasidenib Sales Value by Region (2027-2032)
  9. 6.5 Global Enasidenib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Enasidenib Sales Value (2021-2032)
  12. 6.6.2 North America Enasidenib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Enasidenib Sales Value (2021-2032)
  15. 6.7.2 Europe Enasidenib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Enasidenib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Enasidenib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Enasidenib Sales Value (2021-2032)
  21. 6.9.2 South America Enasidenib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Enasidenib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Enasidenib Sales Value Share by Country, 2025 VS 2032
7 Enasidenib Country-level Sales and Value Analysis
  1. 7.1 Global Enasidenib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Enasidenib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Enasidenib Sales by Country (2021-2032)
  4. 7.3.1 Global Enasidenib Sales by Country (2021-2026)
  5. 7.3.2 Global Enasidenib Sales by Country (2027-2032)
  6. 7.4 Global Enasidenib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Enasidenib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Enasidenib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Enasidenib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Enasidenib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Enasidenib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Enasidenib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Enasidenib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Enasidenib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Enasidenib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Enasidenib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Enasidenib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Enasidenib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Enasidenib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Enasidenib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Enasidenib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Enasidenib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Enasidenib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Enasidenib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Enasidenib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Enasidenib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Enasidenib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Enasidenib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Enasidenib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Enasidenib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Enasidenib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Enasidenib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Enasidenib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Enasidenib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Enasidenib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Enasidenib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Enasidenib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Enasidenib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Enasidenib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Enasidenib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Enasidenib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Enasidenib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Enasidenib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Enasidenib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Enasidenib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Enasidenib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Enasidenib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Enasidenib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Enasidenib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Enasidenib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Enasidenib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Enasidenib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Enasidenib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Enasidenib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Enasidenib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Enasidenib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Enasidenib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Enasidenib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Enasidenib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Enasidenib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Enasidenib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Enasidenib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Enasidenib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Enasidenib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Enasidenib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Enasidenib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Enasidenib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Enasidenib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Enasidenib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Enasidenib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Enasidenib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Enasidenib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Enasidenib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Enasidenib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Enasidenib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Enasidenib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Enasidenib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Enasidenib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Enasidenib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Enasidenib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Enasidenib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Enasidenib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Enasidenib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Enasidenib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Enasidenib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Enasidenib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Enasidenib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Enasidenib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Enasidenib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Enasidenib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Enasidenib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Enasidenib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol Myers Squibb
  2. 8.1.1 Bristol Myers Squibb Company Information
  3. 8.1.2 Bristol Myers Squibb Business Overview
  4. 8.1.3 Bristol Myers Squibb Enasidenib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol Myers Squibb Enasidenib Product Portfolio
  6. 8.1.5 Bristol Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Enasidenib Value Chain Analysis
  2. 9.1.1 Enasidenib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Enasidenib Sales Mode & Process
  6. 9.2 Enasidenib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Enasidenib Distributors
  9. 9.2.3 Enasidenib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst